Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab-based perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer
2020-005452-38Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tremelimumab and enfortumab vedotin in bladder cancer and transitional cell carcinoma (TCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability. Started May 2021; status: active.
02
Drugs
durvalumabtremelimumabenfortumab vedotin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2020-005452-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005452-38.